Ton N Schumacher
Overview
Explore the profile of Ton N Schumacher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
151
Citations
30119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greenwald N, Nederlof I, Sowers C, Ding D, Park S, Kong A, et al.
bioRxiv
. 2025 Feb;
PMID: 39975273
Immune checkpoint inhibition (ICI) has fundamentally changed cancer treatment. However, only a minority of patients with metastatic triple negative breast cancer (TNBC) benefit from ICI, and the determinants of response...
2.
Kuilman T, Schrikkema D, Gadiot J, Gomez-Eerland R, Bies L, Walker J, et al.
Nat Commun
. 2025 Jan;
16(1):649.
PMID: 39809767
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) can mediate tumor regression, including complete and durable responses, in a range of solid cancers, most notably in melanoma. However, its wider application...
3.
Chen X, Leisegang M, Gavvovidis I, Pollack S, Lorenz F, Schumacher T, et al.
Front Immunol
. 2025 Jan;
15():1524629.
PMID: 39776913
Generation of high avidity T cell receptors (TCRs) reactive to tumor-associated antigens (TAA) is impaired by tolerance mechanisms, which is an obstacle to effective T cell therapies for cancer treatment....
4.
Buri M, Shoeb M, Bykov A, Repiscak P, Baik H, Dupanovic A, et al.
Cancer Immunol Res
. 2024 Dec;
13(3):430-446.
PMID: 39642167
The term cancer immunoediting describes the dual role by which the immune system can suppress and promote tumor growth and is divided into three phases: elimination, equilibrium, and escape. The...
5.
Nederlof I, Isaeva O, de Graaf M, Gielen R, Bakker N, Rolfes A, et al.
Nat Med
. 2024 Sep;
30(11):3223-3235.
PMID: 39284953
Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II-III triple-negative breast cancer; however, it is largely unknown for which patients ICI without chemotherapy could...
6.
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
de Gooyer P, Verschoor Y, van den Dungen L, Balduzzi S, Marsman H, Geukes Foppen M, et al.
Nat Med
. 2024 Sep;
30(11):3284-3290.
PMID: 39278994
Mismatch repair deficiency (dMMR) is found in approximately 15% of non-metastatic colon cancers (CCs) and is characterized by a defective DNA mismatch repair system, resulting in hypermutated and highly immunogenic...
7.
Richterich C, Logtenberg M, Jansen M, Toebes M, Bresser K, Borst A, et al.
J Immunol
. 2024 Aug;
213(8):1244-1254.
PMID: 39213127
Neutrophils can efficiently trigger cytotoxicity toward tumor cells and other target cells upon engagement of the IgA receptor CD89. However, the cell-intrinsic factors that influence the induction of cell death...
8.
Sultan H, Takeuchi Y, Ward J, Sharma N, Liu T, Sukhov V, et al.
Nature
. 2024 Jul;
632(8023):182-191.
PMID: 39048822
CD4 T cells can either enhance or inhibit tumour immunity. Although regulatory T cells have long been known to impede antitumour responses, other CD4 T cells have recently been implicated...
9.
Bresser K, Nicolet B, Jeko A, Wu W, Loayza-Puch F, Agami R, et al.
Cell Rep
. 2024 Jun;
43(7):114418.
PMID: 38923456
No abstract available.
10.
Bresser K, Nicolet B, Jeko A, Wu W, Loayza-Puch F, Agami R, et al.
Cell Rep
. 2024 Jun;
43(6):114325.
PMID: 38870014
The sensitivity of malignant tissues to T cell-based immunotherapies depends on the presence of targetable human leukocyte antigen (HLA) class I ligands. Peptide-intrinsic factors, such as HLA class I affinity...